Loading...
XSTO
BONEX
Market cap1.97bUSD
Apr 14, Last price  
309.20SEK
1D
-2.34%
1Q
-22.90%
IPO
868.77%
Name

Bonesupport Holding AB

Chart & Performance

D1W1MN
P/E
152.25
P/S
22.66
EPS
2.03
Div Yield, %
—
Shrs. gr., 5y
5.12%
Rev. gr., 5y
42.04%
Revenues
899m
+52.05%
40,961,00061,755,000104,599,000129,301,00096,623,000155,462,000180,860,000212,885,000328,818,000591,077,000898,727,000
Net income
134m
-45.41%
-51,065,000-59,555,000-110,190,000-128,869,000-176,405,000-161,060,000-101,412,000-85,531,000-68,167,000245,021,000133,754,000
CFO
66m
P
-45,923,000-65,292,000-81,933,000-107,534,000-171,625,000-163,828,000-100,275,000-83,421,000-46,985,000-18,257,00065,702,000
Earnings
Apr 23, 2025

Profile

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
URL
https://www.bonesupport.com
IPO date
Jun 21, 2017
Employees
104
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
898,727
52.05%
591,077
79.76%
328,818
54.46%
Cost of revenue
751,820
568,884
395,952
Unusual Expense (Income)
NOPBT
146,907
22,193
(67,134)
NOPBT Margin
16.35%
3.75%
Operating Taxes
38,870
(229,273)
3,473
Tax Rate
26.46%
NOPAT
108,037
251,466
(70,607)
Net income
133,754
-45.41%
245,021
-459.44%
(68,167)
-20.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,421
27
50,914
BB yield
-0.01%
0.00%
-0.98%
Debt
Debt current
6,929
4,262
5,101
Long-term debt
22,249
30,706
29,801
Deferred revenue
Other long-term liabilities
377
357
344
Net debt
(197,826)
(132,383)
(166,380)
Cash flow
Cash from operating activities
65,702
(18,257)
(46,985)
CAPEX
(1,530)
(820)
(3,279)
Cash from investing activities
(6,265)
(6,060)
(3,279)
Cash from financing activities
(4,752)
(6,703)
42,782
FCF
(30,669)
188,215
(75,003)
Balance
Cash
227,004
167,351
201,281
Long term investments
1,000
Excess cash
182,068
137,797
184,841
Stockholders' equity
(845,043)
(1,018,685)
(1,294,908)
Invested Capital
1,587,473
1,581,703
1,580,534
ROIC
6.82%
15.90%
ROCE
19.79%
3.94%
EV
Common stock shares outstanding
66,608
65,592
64,447
Price
386.80
105.53%
188.20
133.93%
80.45
82.84%
Market cap
25,763,974
108.71%
12,344,414
138.09%
5,184,761
84.12%
EV
25,566,148
12,212,031
5,018,381
EBITDA
154,124
32,265
(57,751)
EV/EBITDA
165.88
378.49
Interest
3,117
970
Interest/NOPBT
14.04%